Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Key facts
- Who runs it
- First Affiliated Hospital Xi'an Jiaotong University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 May 2024
- Ended
- 19 Jul 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- CTPA (computed tomography pulmonary angiography)
- Record updated
- 22 July 2024
- Why it stopped
- The number of patients is not sufficient to support the project.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- The pathological diagnosis was lung cancer
- Pulmonary artery was evaluated by CTA during hospitalization
Who cannot take part
- Patients with a history of PE before diagnosis of lung cancer
- Patients with incomplete clinical data
- Patients with no follow-up data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.
The 2 groups in the trial
- PE group
The CTPA diagnosis suggest pulmonary embolism
Treatment: CTPA (computed tomography pulmonary angiography)
- control group
The CTPA diagnosis did not suggest pulmonary embolism
Treatment: CTPA (computed tomography pulmonary angiography)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 July 2024